The novel mechanism of lenalidomide activity
Lenalidomide acts by a novel drug mechanism—modulation of the substrate specificity of the CRL4[CRBN] E3 ubiquitin ligase. In multiple myeloma, lenalidomide induces the ubiquitination of IKZF1 and IKZF3 by CRL4[CRBN] . Subsequent proteasomal ...
Blood . 2015 Oct 5;126(21):2366–2369. doi: 10.1182/blood-2015-07-567958 The novel mechanism of lenalidomide activity Emma C Fink Emma C Fink 1 Brigham and Women’s Hospital, Division of Hematology, Boston, MA Find articles by Emma C Fink 1 , Benjamin L Ebert Benjamin L Ebert 1 Brigham and Women’s Hospital, Division of Hematology, Boston, MA Find articles by Benjamin L Ebert 1, ✉ Author information Article notes Copyright and License information 1 Brigham and Women’s Hospital, Division of Hematology, Boston, MA ✉ Corresponding author. Received 2015 Jul 1; Accepted 2015 Sep 23; Issue date 2015 No
Explore this link on the map →saved by
related reading
- Lysosome-targeting chimeras evolve | Nature Chemical Biologynature.com
- Targeting telomerase for cancer therapy | Oncogenenature.com
- Protein degradation reaches further outnature.com
- The blood cancer that became solvableworksinprogress.news
- Longevity FAQ - Laura Demingldeming.com
- Mechanisms of Immunosuppression - Holland-Frei Cancer Medicine - NCBI Bookshelfncbi.nlm.nih.gov
- Medical breakthroughs in 2025 - by Saloni Dattaniscientificdiscovery.dev
- Immunotherapy in pediatric malignancies: current status and future perspectives - PMCncbi.nlm.nih.gov
- Sensitizing to Venetoclax treatmentmappingignorance.org
- Sci-Hubsci-hub.box
- Glucocorticoids and Cancer - PMCncbi.nlm.nih.gov
- Interferon-alpha/beta receptor - Wikipediaen.wikipedia.org